ALVO · Alvotech
AI read · Neutral
The AI's read
Alvotech reported Q2 results showing production slowdowns early in the quarter, manufacturing back to plan by quarter-end, BLAs resubmitted, FDA inspection closed with a VAI, and a $165M equity raise alongside reaffirmed 2026 guidance. These cut both regulatory and cash concerns and matter for multiple biosimilars coming 2027–2029. H1 revenue fell to $212M from $306M and the stock is down ~2.5% after the call while RSI sits at 75.2. That combination smells like optimism already baked in or at least buyer fatigue. Bottom line: we lean neutral. Wait for clear U.S. approvals or visible revenue recovery before shifting bullish, given the mixed signals and stretched technicals.